Astria Therapeutics, Inc. (NASDAQ:ATXS) Short Interest Down 9.2% in September

Astria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) saw a significant decline in short interest during the month of September. As of September 30th, there was short interest totalling 3,470,000 shares, a decline of 9.2% from the September 15th total of 3,820,000 shares. Currently, 7.3% of the company's stock are sold short. Based on an average daily volume of 381,000 shares, the short-interest ratio is presently 9.1 days.

Analyst Ratings Changes

A number of equities research analysts recently commented on ATXS shares. Oppenheimer increased their target price on shares of Astria Therapeutics from $25.00 to $26.00 and gave the company an "outperform" rating in a research report on Tuesday, August 13th. Wedbush reissued an "outperform" rating and issued a $22.00 price objective on shares of Astria Therapeutics in a research report on Tuesday, August 13th. TD Cowen assumed coverage on Astria Therapeutics in a research note on Monday, July 29th. They set a "buy" rating and a $35.00 target price on the stock. HC Wainwright reiterated a "buy" rating and issued a $16.00 price target on shares of Astria Therapeutics in a research note on Friday, September 27th. Finally, Evercore ISI raised shares of Astria Therapeutics to a "strong-buy" rating in a research report on Wednesday, August 14th. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Astria Therapeutics has a consensus rating of "Buy" and a consensus price target of $25.20.

Hedge Funds Weigh In On Astria Therapeutics

A number of institutional investors have recently modified their holdings of ATXS. SG Americas Securities LLC acquired a new stake in Astria Therapeutics in the 3rd quarter worth about $155,000. Cubist Systematic Strategies LLC purchased a new position in Astria Therapeutics during the second quarter worth approximately $2,561,000. Nantahala Capital Management LLC purchased a new position in Astria Therapeutics during the second quarter worth about $6,142,000. Susquehanna Fundamental Investments LLC acquired a new position in Astria Therapeutics in the second quarter valued at approximately $400,000. Finally, Millennium Management LLC grew its holdings in shares of Astria Therapeutics by 13.5% during the 2nd quarter. Millennium Management LLC now owns 1,842,063 shares of the biotechnology company's stock worth $16,763,000 after purchasing an additional 218,518 shares during the period. Hedge funds and other institutional investors own 98.98% of the company's stock.

Astria Therapeutics Stock Performance

NASDAQ ATXS traded up $0.42 during trading hours on Tuesday, reaching $11.49. The stock had a trading volume of 151,751 shares, compared to its average volume of 660,365. Astria Therapeutics has a 52-week low of $4.26 and a 52-week high of $16.90. The stock has a fifty day moving average of $11.35 and a 200 day moving average of $10.50. The stock has a market cap of $630.95 million, a P/E ratio of -4.95 and a beta of 0.71.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last released its quarterly earnings data on Monday, August 12th. The biotechnology company reported ($0.43) earnings per share for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.05). On average, equities research analysts forecast that Astria Therapeutics will post -1.72 EPS for the current year.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.